Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.